title: Vedolizumab for induction and maintenance of remission in ulcerative colitis.
abstract: BACKGROUND
  Cellular adhesion molecules play an important role in the pathogenesis of ulcerative colitis, making selective blockade of these molecules a promising therapeutic strategy. Vedolizumab, a recombinant humanized IgG1 monoclonal antibody, inhibits adhesion and migration of leukocytes into the gastrointestinal tract by binding the alpha4beta7 integrin. Animal studies have suggested that vedolizumab may be a useful therapy for ulcerative colitis. This updated systematic review summarizes the current evidence on the use of vedolizumab for induction and maintenance of remission in ulcerative colitis.
  
  
  OBJECTIVE
  The primary objectives were to determine the efficacy and safety of vedolizumab used for induction and maintenance of remission in ulcerative colitis.
  
  
  METHODS
  A computer-assisted search for relevant studies (inception to 15 June 2014) was performed using PubMed, MEDLINE, EMBASE and CENTRAL. References from published articles and conference proceedings were searched to identify additional citations.
  
  
  METHODS
  Randomized controlled trials comparing vedolizumab to placebo or a control therapy for induction or maintenance of remission in ulcerative colitis were included.
  
  
  METHODS
  Two authors independently extracted data and assessed the risk of bias for each trial. The primary outcomes were failure to induce clinical remission and relapse. Secondary outcomes included failure to induce a clinical response, failure to induce endoscopic remission, failure to induce an endoscopic response, quality of life, adverse events, serious adverse events and withdrawal due to adverse events. We calculated the relative risk (RR) and 95% confidence intervals (CI) for each outcome. Data were analyzed on an intention-to-treat basis. The overall quality of the evidence supporting the outcomes was evaluated using the GRADE criteria.
  
  
  RESULTS
  Four studies (606 patients) were included. All of the studies were rated as having a low risk of bias. Pooled analyses revealed that vedolizumab was significantly superior to placebo for induction of remission, clinical response, and endoscopic remission and prevention of relapse. After 4 to 6 weeks of therapy 77% (293/382) of vedolizumab patients failed to enter clinical remission compared to 92% (205/224) of placebo patients (RR 0.86, 95% CI 0.80 to 0.91; 4 studies 606 patients). After 6 weeks of therapy 48% of vedolizumab patients failed to have a clinical response compared to 72% of placebo patients (RR 0.68, 95% CI 0.59 to 0.78; 3 studies 601 patients). After 4 to 6 weeks of therapy 68% of vedolizumab patients failed to enter endoscopic remission compared to 81% of placebo patients (RR 0.82, 95% CI 0.75 to 0.91; 3 studies, b583 patients). After 52 weeks of therapy, 54% of vedolizumab patients had a clinical relapse compared to 84% of placebo patients (RR 0.67, 95% CI 0.59 to 0.77; 1 study, 373 patients). One small study (28 patients) found no statistically significant difference in endoscopic response (RR 1.00, 95% CI 0.62 to 1.61). GRADE analyses indicated that the overall quality of the evidence for the primary outcomes was high for induction of remission and moderate for relapse (due to sparse data 246 events). There was no statistically significant difference between vedolizumab and placebo in terms of the risk of any adverse event (RR 0.99, 95% CI 0.93 to 1.07), or serious adverse events (RR 1.01, 95% CI 0.72 to 1.42). There was a statistically significant difference in withdrawals due to adverse events. Six per cent of vedolizumab patients withdrew due to an adverse event compared to 11% of placebo patients (RR 0.55, 95% CI 0.35 to 0.87; 2 studies, 941 patients). Adverse events commonly reported across the studies included: worsening ulcerative colitis, headache, nasopharyngitis, upper respiratory tract infection, nausea, and abdominal pain.
  
  
  CONCLUSIONS
  Moderate to high quality data from four studies shows that vedolizumab is superior to placebo for induction of clinical remission and response and endoscopic remission in patients with moderate to severely active ulcerative colitis and prevention of relapse in patients with quiescent ulcerative colitis. Moderate quality data from one study suggests that vedolizumab is superior to placebo for prevention of relapse in patients with quiescent ulcerative colitis. Adverse events appear to be similar to placebo. Future trials are needed to define the optimal dose, frequency of administration and long-term efficacy and safety of vedolizumab used for induction and maintenance therapy of ulcerative colitis. Vedolizumab should be compared to other currently approved therapies for ulcerative colitis in these trials.
authors.affiliation: Center for Inflammatory Bowel Diseases, Virginia Commonwealth University Health System Box 980341, Richmond, VA, USA, 23298.
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Bickston
authors.forename: Brian W
authors.initials: BW
authors.lastname: Behm
authors.forename: David J
authors.initials: DJ
authors.lastname: Tsoulis
authors.forename: Jianfeng
authors.initials: J
authors.lastname: Cheng
authors.forename: John K
authors.initials: JK
authors.lastname: MacDonald
authors.forename: Reena
authors.initials: R
authors.lastname: Khanna
authors.forename: Brian G
authors.initials: BG
authors.lastname: Feagan
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000517:prevention & control / Q000628:therapy*; D006801:Humans; D060828:Induction Chemotherapy / Q000379:methods*; D060046:Maintenance Chemotherapy / Q000379:methods*; D016032:Randomized Controlled Trials as Topic; D055502:Secondary Prevention
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C543529:vedolizumab
references.citation: Gastroenterology. 1996 Nov;111(5):1373-80
references.pmid: 8898653
references.citation: Inflamm Bowel Dis. 2012 Aug;18(8):1470-9
references.pmid: 22147460
references.citation: BMJ. 2008 Apr 26;336(7650):924-6
references.pmid: 18436948
references.citation: N Engl J Med. 2006 Mar 2;354(9):924-33
references.pmid: 16510746
references.citation: N Engl J Med. 2013 Aug 22;369(8):711-21
references.pmid: 23964933
references.citation: Inflamm Bowel Dis. 2012 Nov;18(11):2107-19
references.pmid: 22419649
references.citation: Cochrane Database Syst Rev. 2009 Jan 21;(1):CD007571
references.pmid: 19160337
references.citation: Am J Gastroenterol. 2010 Mar;105(3):501-23; quiz 524
references.pmid: 20068560
references.citation: N Engl J Med. 2005 Nov 3;353(18):1912-25
references.pmid: 16267322
references.citation: N Engl J Med. 2012 May 17;366(20):1870-80
references.pmid: 22591293
references.citation: Gastroenterology. 2007 May;132(5):1672-83
references.pmid: 17484865
references.citation: Cochrane Database Syst Rev. 2005 Jan 25;(1):CD004277
references.pmid: 15674937
references.citation: Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005112
references.pmid: 16856078
references.citation: Inflamm Bowel Dis. 2013 Jul;19(8):1691-9
references.pmid: 23591599
references.citation: Inflamm Bowel Dis. 2008 Dec;14(12):1660-6
references.pmid: 18623174
references.citation: N Engl J Med. 2013 Aug 22;369(8):699-710
references.pmid: 23964932
references.citation: N Engl J Med. 2005 Jun 16;352(24):2499-507
references.pmid: 15958805
references.citation: Cochrane Database Syst Rev. 2007 Jan 24;(1):CD006097
references.pmid: 17253580
references.citation: J Immunol. 1994 Jul 15;153(2):517-28
references.pmid: 7517418
references.citation: Br Med J. 1964 Jan 11;1(5375):89-92
references.pmid: 14075156